T-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-jB-p65

Journal of Neuro-Oncology

Volumn 108, Issue 3, 2012, Pages 385-393

  Li, Junyang ^a   Liu, Hongyi ^b   Xing, Biao ^a   Yu, Yanzhe ^a   Wang, Hui ^a   Chen, Gong ^a   Gu, Bing ^a   Zhang, Guofeng ^a   Wei, Dong ^a   Gu, Peiyuan ^a   Li, Meng ^a   Hu, Weixing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Glioma; Inhibitor; Nuclear factor B; Soluble epoxide hydrolase

Indexed keywords

4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; EPOXIDE HYDROLASE; MESSENGER RNA; PYRROLIDINE DITHIOCARBAMATE; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BENZOIC ACIDS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; EPOXIDE HYDROLASES; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UREA;

EID: 84864039219     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0841-4     Document Type: Article

References (34)

1. Ranza E, Mazzini G, Facoetti A, Nano R (2010) In vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell pro-liferation. J Neurooncol 96:349-357. doi:10.1007/s11060-009-9975-4
2. Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M (2011) Efficacy of protracted dose-dense temozolo-mide in patients with recurrent high-grade glioma. J Neurooncol 103:585-593. doi:10.1007/s11060-010-0423-2
3. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS (2011) Phase II study of carboplatin, irinotecan, and bevacizumab for bev-acizumab naive, recurrent glioblastoma. J Neurooncol. doi:10.10 07/s11060-011-0722-2
4. Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Fried-man HS (2011) Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. doi: 10.1007/s11060-011-0631-4
5. Davis BB, Liu JY, Tancredi DJ, Wang L, Simon SI, Hammock BD, Pinkerton KE (2011) The anti-inflammatory effects of sol-uble epoxide hydrolase inhibitors are independent of leukocyte recruitment. Biochem Biophys Res Commun 410:494-500. doi:10.1016/j.bbrc.2011.06.008
6. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD (2011) Soluble epoxide hydro-lase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci USA 108:9038-9043. doi:10.1073/pnas.1103482108
7. Ni GH, Chen JF, Chen XP, Yang TL (2011) Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular dis-eases. Pharmazie 66:153-157
8. Schebb NH, Huby M, Morisseau C, Hwang SH, Hammock BD (2011) Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors. Anal Bioanal Chem 400:1359-1366. doi:10.1007/s00216-011-4861-2
9. Koeners MP, Wesseling S, Ulu A, Sepulveda RL, Morisseau C, Braam B, Hammock BD, Joles JA (2011) Soluble epoxide hydrolase in the generation and maintenance of high blood pres-sure in spontaneously hypertensive rats. Am J Physiol Endocrinol Metab 300:E691-E698. doi:10.1152/ajpendo.00710.2010
10. Panigrahy D, Kaipainen A, Greene ER, Huang S (2010) Cyto-chrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev 29:723-735. doi:10.1007/s10555-010-9264-x
11. Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C, Hammock BD (2009) Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 156:284-296. doi:10.1111/j.1476-5381.2008. 00009.x
12. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chia-mvimonvat N, Hammock BD (2010) Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79:880-887. doi:10.1016/ j.bcp.2009.10.025
13. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, DegraffLM, Foley JF, Torphy R, Ronnekleiv OK, Tomer KB, Lee CR, Zeldin DC (2011) Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J. doi:10.10 96/fj.11-188300
14. Spector AA, Fang X, Snyder GD, Weintraub NL (2004) Ep-oxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43:55-90. doi:S0163782703000493 (Pubitemid 37433867)
15. Deng Y, Theken KN, Lee CR (2010) Cytochrome P450 epoxy-genases, soluble epoxide hydrolase, and the regulation of car-diovascular inflammation. J Mol Cell Cardiol 48:331-341. doi:10.1016/j.yjmcc.2009.10.022
16. Tran L, Kompa AR, Wang BH, Krum H (2011) Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients. Cardiovasc Ther. doi:10.1111/j.1755-5922.2011.00 282.x
17. Liu JY, Qiu H, Morisseau C, Hwang SH, Tsai HJ, Ulu A, Chi-amvimonvat N, Hammock BD (2011) Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model. Toxicol Appl Pharmacol 255:200-206. doi:10.1016/j.taap.2011.06.017
18. De Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24-37. doi:10.1038/nrc1782 (Pubitemid 43053650)
19. Enayetallah AE, French RA, Grant DF (2006) Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. J Mol Histol 37:133-141. doi:10.10 07/s10735-006-9050-9
20. Yang MD, Wu CC, Chiou SH, Chiu CF, Lin TY, Chiang IP, Chow KC (2003) Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma. Oncol Rep 10:271-276
21. Roques M, Bagrel D, Magdalou J, Siest G (1991) Expression of arylhydrocarbon hydroxylase, epoxide hydrolases, glutathione S-transferase and UDP-glucuronosyltransferases in H5-6 hepa-toma cells. Gen Pharmacol 22:677-684
22. Chaudhary KR, Abukhashim M, Hwang SH, Hammock BD, Seubert JM (2010) Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido) -cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. J Cardio-vasc Pharmacol 55:67-73. doi:10.1097/FJC.0b013e3181c37d69
23. Zhao Y, Banerjee S, Lejeune WS, Choudhary S, Tilton RG (2011) NF-kappaB-inducing kinase increases renal tubule epi-thelial inflammation associated with diabetes. Exp Diabetes Res 2011:192564. doi: 10.1155/2011/192564
24. Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, Ren B, Natarajan R (2008) Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 283:26771-26781. doi:10.1074/jbc. M802800200
25. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lih FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC, Lee CR (2011) Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 25:703-713. doi:10.1096/fj.10-171488
26. Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, Hughes WM Jr, Metreveli N, Rosenberger DS, Singh M, Vacek TP, Rodriguez WE, Ayotunde A, Tyagi SC (2008) Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhi-bition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol 215:771-781. doi:10.1002/jcp.21356 (Pubitemid 351632699)
27. Seitz CS, Lin Q, Deng H, Khavari PA (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95:2307-2312 (Pubitemid 28145937)
28. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421:639-643. doi:10.1038/nature 01283 (Pubitemid 36227672)
29. Karin M (2009) NF-kappaB as a critical link between inflam-mation and cancer. Cold Spring Harb Perspect Biol 1:a000141. doi:10.1101/cshperspect. a000141
30. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11:558-572. doi:10.1038/nrc3090
31. Witzel II, Koh LF, Perkins ND (2010) Regulation of cyclin D1 gene expression. Biochem Soc Trans 38:217-222. doi:10.1042/ BST0380217
32. Fox KE, Colton LA, Erickson PF, Friedman JE, Cha HC, Keller P, MacDougald OA, Klemm DJ (2008) Regulation of cyclin D1 and Wnt10b gene expression by cAMP-responsive element-binding protein during early adipogenesis involves differential promoter methylation. J Biol Chem 283:35096-35105. doi: 10.1074/jbc.M806423200
33. Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL, Dong Y, Hou L, Hu G, Luo C, Chen J, Lu Y (2011) Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol. doi:10.1007/s11060-011-0692-4
34. Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piw-nica-Worms H (1994) Cell cycle regulation of the p34cdc2 inhibitory kinases. Mol Biol Cell 5:989-1001